Develops drug candidates for autoimmune and inflammatory diseases, including antibody and oral therapies for patients with multiple sclerosis and other immune conditions.
10-K for FY2025, filed Mar 16, 2026We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of…View ↗
Our lead I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly…View ↗
In addition to obexelimab, we are developing orelabrutinib, a Bruton’s Tyrosine Kinase inhibitor (“BTK”), for progressive forms of multiple…View ↗
We also have two early-development product candidates: ZB021 and ZB022. ZB021 is an oral IL-17AA/AF inhibitor designed to block both…View ↗
The company can earn revenue by licensing drug-candidate rights: a partner pays an upfront fee, with additional payments tied to development or commercial milestones and royalties on sales.
10-K for FY2025, filed Mar 16, 2026In January 2025, we entered into the Zai License Agreement, with Zai, under which we granted to Zai an exclusive sublicense to develop and…View ↗
$10M
10-K for FY2025, filed Mar 16, 2026
$10M ↗
Bristol Myers Squibb holds licensed rights to develop and commercialize obexelimab in several markets, and Zai Lab has an exclusive sublicense for ZB001 in greater China. If products are approved, Zenas plans to sell directly in the U.S. and Europe and use third parties in Asia and other regions.
10-K for FY2025, filed Mar 16, 2026We hold global development and commercialization rights to obexelimab, excluding Japan, Taiwan, South Korea, Singapore, Hong Kong and…View ↗
If our product candidates receive FDA or EMA approval, we intend to build our own commercialization infrastructure in the U.S. and Europe…View ↗
We also have in-licensed the development and commercialization rights to ZB001 (also known as VRDN-001), an IGF-1R monoclonal antibody, and…View ↗
No. It lost $377.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
$10MView ↗
8-K, filed Aug 13, 2026
- CFO to transition to Strategic Advisor to the Board Chair at the end of September -View ↗
Competes with Amgen, Sanofi, Acepodia, F. Hoffmann-La Roche, Novartis, TG Therapeutics, Biogen, Bayer, Teva Neuroscience, Bristol Myers Squibb, Genzyme, Banner Life Sciences, Janssen Pharmaceuticals, Cycle Pharmaceuticals, Immunic Therapeutics, AB Science, GSK, AstraZeneca, RemeGen, and UCB
10-K for FY2025, filed Mar 16, 2026Uplizna® (inebilizumab-cdon), an anti-CD19 antibody marketed by Amgen Inc.;View ↗
Loading...